RESUMO
Pancreatic cancer is one of the cancers with poor prognosis at present, which has high resistance to various anti-tumor drugs as a result of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment. P2X7 receptors are extracellular adenosine triphosphate(ATP)-gated nonselective cation channels, which have many biological functions including being involved in cell signal transduction and cytokine secretion, mediate cell survival and growth. Studies have shown that P2X7 receptor is highly expressed in pancreatic cancer and promotes the proliferation, migration and invasion of pancreatic cancer cells by supporting proliferation of pancreatic stellate cells and regulating the expressed of the MMP2/MMP9 protein. The paper reviews the recent research advances of P2X7 receptor in pancreatic cancer.
RESUMO
As the P2X receptor family has become a research hotspot in recent years, the study on P2X7 receptor has also received extensive attention. P2X7 receptor (P2X7R) is a dual-transmembrane cation-channel receptor, which is gated in vivo by adenosine triphosphate (ATP) and can be activated. Activated P2X7 receptor can produce such effects as cationic channel opening, signal pathway activation, inflammatory mediator release and cell apoptosis. It plays an important role in the development of various tumors and inflammatory diseases. Studies have shown that the abnormal expression of P2X7 receptor affects the occurrence and development of breast cancer by activating a series of signaling pathways, which is expected to become a new target for designing anti-breast cancer drugs. Other studies have shown that multiple microRNAs can promote the occurrence and development of breast cancer by regulating the expression of P2X7 receptor gene. In this review, we reviewed the recent research advances of P2X7 receptor and the relationship between breast cancer and its abnormal expression.